Reuters logo
BRIEF-Valeritas' V-GO wearable insulin delivery device provided significant and sustained A1C reductions
May 4, 2017 / 8:15 PM / 5 months ago

BRIEF-Valeritas' V-GO wearable insulin delivery device provided significant and sustained A1C reductions

May 4 (Reuters) - Valeritas Holdings Inc

* Valeritas V-GO wearable insulin delivery device provided significant and sustained A1C reductions and achieved a1c glycemic targets in patients with type 2 diabetes Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below